Osteologix/Servier. I keep a running log of deals and it clocked in as the weakest P2/P3 deal. Upfront being undisclosed tells you something.
Securing an SPA was a good step and that should help as far as raising equity financing to run a pivotal study. But I still think they'll have a lot of trouble securing FDA approval due to catastrophic risk from hyper allergic reactions in europe. The FDA bar for risk in a well served market is low. The comparable is Indevus and their injectable testosterone that's been delayed for several years due to the european experience of 1 in a million coughing fits which self resolve. Death vs coughing. You can worry about that in 3-4 years after they file for approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.